{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:52:38Z","timestamp":1791924758991,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","heartandlung.org","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart & Lung"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.hrtlng.2014.11.005","type":"journal-article","created":{"date-parts":[[2015,1,13]],"date-time":"2015-01-13T18:09:18Z","timestamp":1421172558000},"page":"141-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Managing the acute coronary syndrome patient: Evidence based recommendations for anti-platelet therapy"],"prefix":"10.1016","volume":"44","author":[{"given":"Michael G.","family":"Clark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Beavers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrtlng.2014.11.005_bib1","article-title":"2014 AHA\/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.hrtlng.2014.11.005_bib2","doi-asserted-by":"crossref","first-page":"917","DOI":"10.4065\/84.10.917","article-title":"Acute coronary syndromes: diagnosis and management, Part I","volume":"84","author":"Kumar","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.hrtlng.2014.11.005_bib3","series-title":"The ESC Textbook of Cardiovascular Medicine","first-page":"333","article-title":"Acute coronary syndromes: pathophysiology, diagnosis and risk stratification","author":"Hamm","year":"2009"},{"issue":"3","key":"10.1016\/j.hrtlng.2014.11.005_bib4","first-page":"e28","article-title":"Heart disease and stroke statistics\u20132014 update: a report from the American Heart Association","volume":"129","author":"Go","year":"2014","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.hrtlng.2014.11.005_bib5","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA guideline for the management of st-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"O'Gara","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hrtlng.2014.11.005_bib6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.hrtlng.2014.11.005_bib7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/HPC.0b013e318073bd3c","article-title":"Multidisciplinary rounds (MDR): an implementation system for sustained improvement in the American Heart Association's Get With the Guidelines programs","volume":"6","author":"Ellrodt","year":"2007","journal-title":"Crit Cardiol"},{"issue":"9","key":"10.1016\/j.hrtlng.2014.11.005_bib8","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacc.2011.02.003","article-title":"President's page: team-based care: a solution for our health care delivery challenges","volume":"57","author":"Brindis","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.hrtlng.2014.11.005_bib9","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1161\/CIR.0b013e31826890b0","article-title":"Evolution of critical care cardiology: transformation of the cardiovascular intensive care unit and the emerging need for new medical staffing and training models: a scientific statement from the American Heart Association","volume":"126","author":"Morrow","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.hrtlng.2014.11.005_bib10","series-title":"Methodology Manual and Policies From the ACCF\/AHA Task Force on Practice Guidelines","year":"2009"},{"issue":"23","key":"10.1016\/j.hrtlng.2014.11.005_bib11","first-page":"e663","volume":"127","author":"Anderson","year":"2013","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hrtlng.2014.11.005_bib12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/CIRCULATIONAHA.109.853069","article-title":"New P2Y12 inhibitors","volume":"121","author":"Cattaneo","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.hrtlng.2014.11.005_bib13","unstructured":"Brilinta prescribing information. AstraZeneca, LP., Wilmington, DE, USA. Available at: http:\/\/www1.astrazeneca-us.com\/pi\/brilinta.pdf; Accessed 03.10.13."},{"key":"10.1016\/j.hrtlng.2014.11.005_bib14","unstructured":"Bristol-Myers Squibb Sanofi-aventis, Accessed 03.10.13."},{"key":"10.1016\/j.hrtlng.2014.11.005_bib15","series-title":"Effient (Prasugrel) [Package Insert]","year":"2012"},{"issue":"24","key":"10.1016\/j.hrtlng.2014.11.005_bib16","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1161\/CIR.0b013e318202f701","volume":"122","author":"Abraham","year":"2010","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.hrtlng.2014.11.005_bib17","first-page":"e82","volume":"110","author":"Antman","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hrtlng.2014.11.005_bib18","first-page":"930","article-title":"Dose comparisons of clopidogrel and aspirin in acute coronary syndromes","volume":"363","author":"Mehta","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"9748","key":"10.1016\/j.hrtlng.2014.11.005_bib19","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial study","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.hrtlng.2014.11.005_bib20","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.jacc.2011.06.044","volume":"58","author":"Patti","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.hrtlng.2014.11.005_bib21","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1161\/CIRCULATIONAHA.109.192663","volume":"120","author":"Kushner","year":"2009","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.hrtlng.2014.11.005_bib22","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jacc.2006.06.049","article-title":"Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non\u2013ST-segment elevation acute coronary syndrome undergoing coronary stenting","volume":"48","author":"Cuisset","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hrtlng.2014.11.005_bib23","first-page":"e600","article-title":"Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?","volume":"114","author":"O'Donoghue","year":"2006","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.hrtlng.2014.11.005_bib24","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacc.2012.11.040","volume":"61","author":"Frelinger","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.hrtlng.2014.11.005_bib25","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.hrtlng.2014.11.005_bib26","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"9665","key":"10.1016\/j.hrtlng.2014.11.005_bib27","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","article-title":"Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial","volume":"373","author":"Montalescot","year":"2009","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.hrtlng.2014.11.005_bib28","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1161\/CIRCULATIONAHA.109.927582","article-title":"Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) Trial subgroup analysis","volume":"122","author":"Steg","year":"2010","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.hrtlng.2014.11.005_bib29","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","article-title":"Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"124","author":"Mahaffey","year":"2011","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.hrtlng.2014.11.005_bib30","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hrtlng.2014.11.005_bib31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/eurheartj\/ehm545","article-title":"Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease","volume":"29","author":"Wallentin","year":"2008","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.hrtlng.2014.11.005_bib32","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.jacc.2012.02.042","article-title":"Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary artery disease: the Recovery Trial","volume":"59","author":"Price","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.hrtlng.2014.11.005_bib33","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIR.0b013e3181ee08ed","article-title":"ACCF\/AHA clopidogrel clinical alert: approaches to the FDA \u201cBoxed warning\u201d: a report of the American college of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association","volume":"122","author":"Holmes","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.hrtlng.2014.11.005_bib34","unstructured":"CYP2C19 Test: Product Information. Nanosphere, Inc. Available at: http:\/\/www.nanosphere.us\/products\/cyp2c19-test; Accessed 14.11.14."},{"key":"10.1016\/j.hrtlng.2014.11.005_bib35","unstructured":"Spartan RX CYP2C19 System: Product Information. Spartan Bioscience Inc. Available at: http:\/\/www.spartanbio.com\/products\/spartan-rx\/performance\/; Accessed 14.11.14."},{"issue":"6","key":"10.1016\/j.hrtlng.2014.11.005_bib36","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jacc.2007.01.003","volume":"49","author":"Grines","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.hrtlng.2014.11.005_bib37","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1001\/jama.293.17.2126","article-title":"Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents","volume":"293","author":"Iakovou","year":"2005","journal-title":"J\u00a0Am Med Assoc"},{"issue":"24","key":"10.1016\/j.hrtlng.2014.11.005_bib38","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1161\/CIRCULATIONAHA.106.618066","article-title":"Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER Registry","volume":"113","author":"Spertus","year":"2006","journal-title":"Circulation"},{"issue":"2 suppl","key":"10.1016\/j.hrtlng.2014.11.005_bib39","doi-asserted-by":"crossref","first-page":"e326S","DOI":"10.1378\/chest.11-2298","article-title":"Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Douketis","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.hrtlng.2014.11.005_bib40","unstructured":"American Dental Association. Anticoagulant, Antiplatelet Medications and\u00a0Dental Procedures. Available from: http:\/\/www.ada.org\/2526.aspx?currentTab=2; Accessed 24.09.13."},{"issue":"6","key":"10.1016\/j.hrtlng.2014.11.005_bib41","first-page":"1061","article-title":"Guideline: management of antithrombotic agents for endoscopic procedures","volume":"70","year":"2009","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.hrtlng.2014.11.005_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2014.03.021","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary","author":"January","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"14","key":"10.1016\/j.hrtlng.2014.11.005_bib43","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1161\/01.CIR.0000091201.39590.CB","article-title":"Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study","volume":"108","author":"Peters","year":"2003","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.hrtlng.2014.11.005_bib44","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1001\/archinte.165.21.2508","article-title":"Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study","volume":"165","author":"Gehi","year":"2005","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.hrtlng.2014.11.005_bib45","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ahj.2005.02.038","article-title":"Long-term adherence with cardiovascular drug regimens","volume":"151","author":"Kulkarni","year":"2006","journal-title":"Am Heart J"},{"issue":"10","key":"10.1016\/j.hrtlng.2014.11.005_bib46","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/CIRCULATIONAHA.109.919456","article-title":"Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND Study","volume":"121","author":"Gurbel","year":"2010","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.hrtlng.2014.11.005_bib47","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jacc.2010.02.072","article-title":"Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) Study","volume":"56","author":"Angiolillo","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.hrtlng.2014.11.005_bib48","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2012.03.050","article-title":"Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study","volume":"60","author":"Alexopoulos","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.hrtlng.2014.11.005_bib49","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.jacc.2013.11.032","article-title":"Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: results of the SWAP-2 Study (Switching Anti Platelet-2)","volume":"63","author":"Angiolillo","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.hrtlng.2014.11.005_bib50","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update","volume":"94","author":"Scott","year":"2013","journal-title":"Clin Pharmacol Ther"}],"container-title":["Heart & Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956314004208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956314004208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T05:23:40Z","timestamp":1539667420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0147956314004208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0147956314004208"],"URL":"https:\/\/doi.org\/10.1016\/j.hrtlng.2014.11.005","relation":{},"ISSN":["0147-9563"],"issn-type":[{"value":"0147-9563","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing the acute coronary syndrome patient: Evidence based recommendations for anti-platelet therapy","name":"articletitle","label":"Article Title"},{"value":"Heart & Lung","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrtlng.2014.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}